Higher Productivity

At the initial stages, Elea’s pathology lab automation tool will change the way clinicians and any other staff in labs work. Elea sees an opportunity to increase productivity in the manual pathology lab workflows.

“We basically turn this all around, and all of the steps are much more automated. Doctors speak to Elea, the Medical technical assistants speak to Elea, tell them what they see, what they want to do with it,” Elea CEO and co-founder Dr. Christoph Schröder said.

With its AI-powered tool, the startup will replace legacy information systems and shift workflows to AI-based operating systems capable of deploying speech-to-text transcriptions to reduce the time needed to make diagnosis.

Elea has been running its digital pathology systems with its first batch of users for about half a year. The healthcare AI solutions startup says its systems have effectively redacted the time that labs take to generate about 50% of their reports to two days.

“Elea is the agent, performs all the tasks in the system and prints things, prepares the slides, for example, the staining and all those things, so that tasks go much, much quicker, much, much smoother. It doesn’t really augment anything, it replaces the entire infrastructure,” Schröder added.

Scaling Initial Product

Elea is developing several large language models by fin-tuning data and specialist information to facilitate core capabilities in pathology lab contexts. The startup embeds speech-to-text capabilities to transcribe voice notes. It also embeds text-to-structure capabilities, allowing its systems to convert transcribed voice notes into active directions that power actions of AI agents.

These actions include sending instructions to lab kits to facilitate workflows. Currently, the focus of the digital pathology systems startup is to scale its initial product. The integrated system can stack up and compound gains by replacing tedious tasks. Elea’s pitch to labs shows that processes that could take two to three weeks can be achieved within hours or days.

The startup offers users a range of touch points. Lab staff can access the system through iPad, web, or Mac applications. Once Elea has developed its lab use case fully, it will shift to areas where AI application in healthcare is widespread. The company plans to support doctors in capturing patient interactions while focusing strongly on workflow.

The Risk Factor

Although automating pathology labs with AI will lead to higher outputs, it could pose a challenge to checks because staff have to deal with huge volumes of data. Schröder sees this as a risk. He however argues that his company has developed a feature that allows AI to identify potential gaps through prompts that encourage doctors to review outputs again.

“We call it a second pair of eyes, where we evaluate previous findings reports with what the doctor said right now and give him comments and suggestions,” he says.

The other risk that Elea AI technology poses is breach of patient confidentiality due to reliance on cloud-based processing as opposed to on-premise processing that labs can control. Schröder says his startup addresses this issue by separating patient identity from diagnostic outputs.

“It’s always anonymous along the way, every step just does one thing, and we combine the data on the device where the doctor sees them. We have basically pseudo IDs that we use in all of our processing steps, that are temporary, that are deleted afterward, but for the time when the doctor looks at the patient, they are being combined on the device for him,” Elea CEO said.

Schröder said that the company stores patient data in servers that comply with stringent data privacy laws.

“We work with servers in Europe, ensuring that everything is data privacy compliant. Our lead customer is a publicly owned hospital chain, called critical infrastructure in Germany. We needed to ensure that, from a data privacy point of view, everything is secure. And they have given us the thumbs up,” he added.

Founded in early 2024, Elea has already signed a partnership with a leading German hospital group that processes up to 70,000 cases each year.

The post German Startup, Elea Leverages AI to Boost Productivity in Pathology Labs appeared first on Tech Research Online.

Teresa Graham, CEO of Roche Pharmaceuticals said of the exclusive collaboration and licensing agreement, “We are excited to collaborate with Zealand Pharma and develop this promising therapy, which we hope will provide people living with obesity and related comorbidities a new treatment option,”

The Zealand Pharma deal highlights the growing investments in biotech obesity drugs as pharma giants speed up for developing new weight loss treatments. Under the deal, Zealand Pharma will get a payment of $1.65 billion. Other milestone payments summing up to $5.3 billion will be based on Phase 3 trial results and sales performance, Roche said.

The Roche Zealand Pharma Deal

The Roche Zealand Pharma agreement includes an upfront payment of $280 million for Zealand Pharma and with some further milestone payments worth potentially a total of $5.3 billion. The agreement gives Roche exclusive global rights for the development, manufacturing, and marketing of the obesity drug candidate.

In the United States and Europe, Zealand and Roche will together do the commercialization of Petrelintide.  While Roche will hold exclusive commercialization rights for the rest of the world. Profits and losses for Petrelintide, along with a fixed-dose of Roche’s CT-388, will be shared equally, according to Roche.

Competition Heats Up

The Zealand Pharma partnership puts Roche in competition with big pharmaceutical companies, such as Novo Nordisk and Eli Lilly. These drugs have changed the market. It enables patients to lose substantial amounts of weight and reduce the risk of obesity-related conditions. This deal is Roche’s bet that it can push a breakthrough therapy to market successfully, and it could gain an edge in competitiveness in the multi-billion-dollar-obesity-drug market.

As the global fight against obesity intensifies, Roche’s obesity drug collaboration with Zealand Pharma could mark the beginning of a new era in weight loss treatments. The success of this partnership will be closely watched as both companies work to bring a new, innovative therapy to patients worldwide.

The post Roche Secures Zealand Pharma’s Obesity Drug in $5.3 Billion Deal appeared first on Tech Research Online.

Getinge said, “Growth was particularly strong in ventilators. Consumables in extracorporeal life support in its biggest unit, Acute Care Therapies, and sterile transfer in the smaller business area, Life Science, also showed solid performance.”

Getinge Q4 Profit Beats Estimates

Getinge’s Q4 profits exceed market expectations, highlighting the company’s dedication even while facing economic challenges. The company’s high profits in the last quarter were a result of strong demand for its surgical, life-saving medical devices and improvements in operational efficiency.

Analysts had predicted stable growth, but the actual performance by Getinge has been better than expected, strengthening its position in the medical technology sector. While predicting a 2 to 5% sales increase for 2025, Getinge said, “Despite geopolitical uncertainties and potential trade barriers, our industry is likely to remain relatively stable, driven by long-term healthcare needs and hospitals’ willingness to invest”.

Getinge, the leading manufacturer of medical equipment products, ventilators, cardiovascular, and sterilizers used in healthcare facilities globally. The firm’s supply chain was effective in light of disrupted and inflationary factors that ensured that the revenues would continue to rise with time.

The unexpected increase in Getinge’s Q4 profit was welcomed by investors, making the share price of the medical manufacturer jump to its highest level in months. Strong investor sentiment and optimism about future profitability have boosted the stock above sector averages.

Future Outlook for Getinge

The strong fourth-quarter results position the medical equipment manufacturer Getinge with sustained growth prospects. Getinge intends to use capital gains toward innovation investments and worldwide market growth expansion in addition to solid financial management.

According to industry experts, Getinge can sustain profitability through their medical advancements together with a cost efficiency focus. The increasing demand for advanced medical technologies points toward getinge’s ability to keep steadily growing through 2025 and beyond

Getinge said, “Structural and cost efficiency measures boosted the quarterly operating margin. Its adjusted EBITA margin rose to 19.4% from 13.3% a year ago”.

The post Medical Gear Maker Getinge Reports Strong Q4, Investors Drive Shares Higher by 8% appeared first on Tech Research Online.

CNBC reported that the new partnership is aimed at boosting Suki AI healthcare efforts to develop Q&A and patient summary features using the Vertex AI platform. This Google Cloud platform enables developers to tune, train, and deploy varying AI applications and models.

Improving Suki Assistant

Suki’s initial AI product, Suki Assistant, makes it easy for doctors to record patient visits and automatically convert them into clinical notes. By doing so, the AI assistant eliminates the menial task of taking notes manually.

Through the Suki Google Cloud partnership, the AI startup will push these capabilities a notch higher. It marks the next frontier for the company by offering Suki assistant users with a more assistive technology.

“We were never really building a clinical documentation tool only, it was supposed to be an assistant. An assistant can help you with documentation, but it can also start doing other things,” Suki Founder and CEO Punit Soni said.

Range of New Features

Suki says that leveraging all the patient data available could automatically save clinicians between 15 and 30 minutes that they spend searching patient information. Suki’s AI startup partnership with Google Cloud offers new features that enable doctors to ask questions first and retrieve relevant information about the medical history of their patients.

Doctors will also be able to read patient’s biographical information, their visit history, and their reason for visit with a single click. The Suki and Google Cloud features will generate summaries for users highlighting details like patient’s age, chronic illnesses, previous prescriptions, and any other medical problems.

Where doctors have specific questions regarding a patient, they can use the AI startup’s Q&A button to enter queries. Users can query the patient database using prompts such as ‘What vaccines did the patient take?’ or ‘show me his last A1C’.

“To me, this is actually a larger trend of the AI design, or AI-ification, of health care”, Soni added.

The patient summary feature is already available to selected clinicians. Suki says general availability of this feature and the Q&A will commence early 2025. The company says that initially, the Q&A feature will respond to queries based on patient data. However, the Suki will expand this scope with time. Users will not pay more to use the new features.

Addressing Health Pain Points

Suki’s healthcare technology is designed to address pain points in delivery of health services in the US. Administrative tasks are a leading cause of burnouts among healthcare workers in the country that medical executives are keen to address. Overally, clinicians spend close to 28 hours each week performing administrative tasks. This includes close to 9 hours on patient documentation alone.

Tech tools that automate these tasks like Suki have gained popularity and attracted investors. In October 2024, the company closed a $70 million funding round. Currently, Suki’s tech solution is being used by 350 clinics and health systems across the US. The healthcare AI startup tripled its customer base this year. Suki is looking to stand out in the highly competitive market with its new offerings.

The post Suki AI Partners With Google Cloud to Improve Assistive Tech in Healthcare appeared first on Tech Research Online.

Regulatory Clearance

Based on the tech company’s 51.7 million outstanding shares, the CompuGroup medical deal is valued at approximately $1.2 billion. CVC has been negotiating the deal after it raised €26 billion in 2023 last year for the biggest buyout fund in the world.

The lowest acceptable threshold for the deal is set at 17%. The company was seen to contrast its peers that were forced to either adjust their expectations or delay their fundraising efforts. CVC’s financial statements show that the capital firm deployed about €13.4 billion between January and June this year.

Maintaining Founder Interests

CompuGroup’s supervisory board plans to recommend that offer for shareholder approval after review. The two companies have signed a strategic partnership as they await completion of the deal. CVC ‘s new investment will enable CompuGroup’s founding Gotthardt family to stay invested in the business just as they were before.

In the CompuGroup medical premium deal, the Gotthardt family and its other investment vehicles will retain about 50.1% stakes. CompuGroup was founded by Frank Gotthardt in 1987. Frank, his dentist wife Brigitte Gotthardt, their son Daniel Gotthardt, and another stakeholder, Reinhard Koop are the majority owners of the company.

Performance and Changes

In July this year, CompuGroup named Daniel Gotthardt as the new CEO after terminating Michael Rauch’s contract early. In its profit alert, the company forecasted a dip in operating profits. The forecasts were based on challenges it had been encountering serving doctors and health facilities.

The profit dip forecasts caused company stocks to tumble. CompuGroup share prices dipped to a 10-year low after the company reduced its 2024 fiscal guidance. The company’s shares had declined by 57% since the beginning of the year. This changed on Friday December 6, 2024 after they surged by 31%.

CompuGroup offers Ambulatory Information Systems and IT services for pharmacies and hospitals. Its software helps doctors and hospitals to manage patient data. In 2023, the company’s total revenue stood at €1.19 billion. The company’s third quarter revenues amounted to €283.4 million. Headquartered in Koblenz Germany, CompuGroup operates in 19 countries and has 8,700 employees. Its software products are used in 60 countries

The post CVC Acquires Germany’s CompuGroup in a $1.2 Billion Equity Deal appeared first on Tech Research Online.

According to CNBC, the FDA approved Apple sleep apnea feature is one of Apple’s moves to position its wearable products as simple and cheaper alternatives to existing healthcare devices.

Diagnosis Challenge

Sleep apnea affects about 30 million people across the US. However, statistics from the American Medical Association show that only 6 million of those affected have been diagnosed with the condition.

To get a diagnosis, sleep apnea patients must take home or in-lab tests that require overnight monitoring to get a diagnosis. A 2022 study showed that the average cost of an in-lab test is about $3,000. Although at-home tests may be less costly, patients would still part with hundreds of dollars.

Apple’s Series 10 Watch makes it easier for patients who have not been tested to identify signs of sleep apnea.

“We are so excited about the incredible impact this feature can make for the millions of people living with undiagnosed sleep apnea,” Apple’s VP of Health, Dr. Sumbul Desai said.

The FDA approved Apple sleep track feature will particularly be useful to patients who stay alone. Sleep apnea causes breathing to stop and start repeatedly throughout the night. When left untreated, the sleep disorder can cause fatigue and other health complications like hypertension, heart problems, and Type 2 diabetes.

Apple’s Sleep Apnea Data

Doctors say that data from Apple Watch Series 10 should be treated with caution. According to Missouri-based physician, Dr. David Kuhlmann, insurance companies are less likely to pay for sleep apnea therapies such as CPAP based on data from FDA approved Apple’s sleep apnea detection feature.

Apple Watch Series 10 users will have to get official diagnosis from healthcare providers to access therapy. This will increase the number of patients who visit healthcare providers. The visits will help to reduce the overall cost of healthcare in the US as early detection of the condition can prevent the costly treatment associated with serious conditions.

“By finding out that they have these underlying sleep disorders and getting them treated, it could potentially actually help save expenses and help improve quality of life,” Kuhlmann said.

Apple’s New Products

Apple Watch Series 10 is among the new Apple Intelligence products the tech giant launched last week. Designed to support user health, the new Watch lineup will be available starting Friday, September 20.

“Around the world, Apple Watch has had an immeasurable positive impact on people by helping them stay healthy, active, safe, and connected to the things that matter to them, and it’s helped save countless lives along the way,” Apple’s Chief Operating Officer, Jeff Williams said.

Apple’s sleep apnea detection feature analyzes breathing during sleep and uses an accelerometer to identify disturbances. The accelerometer measures wrist movements that point to disruptions to normal breathing patterns. Apple Watches generate metrics that classify breathing as either elevated or not elevated.

Users can access their metrics on the Health app. The devices analyze breathing disturbance data once each month and notify users of consistent signs of moderate or severe sleep apnea. Apple used extensive data on clinical-grade sleep apnea tests to develop the notification algorithm used in its Watch Series 10.

The post The FDA Approved Apple’s Sleep Apnea Detection Feature appeared first on Tech Research Online.

Imidex is an AI-powered medical device firm that specializes in early lung cancer detection while Orbit Genomics is a DNA-sequencing technology company.

Precision in Detection

Imidex developed the FDA-approved VisiRad XR device. The device utilizes AI and is capable of detecting tiny lung nodules in chest X-rays. This procedure is much more scalable than the CT scans that high-risk individuals are asked to take.

According to Imidex, the VisiRad XR has an 83% sensitivity rate. The company holds that its platform can facilitate identification of suspicious masses in a wide population and refer more individuals to follow-up tests.

Orbit Genomics uses the OrbiSeq-L to diagnose lung cancer in patients who have pulmonary nodules detected through low-dose CT. The company plans to commence clinical trials on OrbiSeq-L

“By leveraging chest X-ray, we have the ability to opportunistically identify millions more patients with pulmonary nodules that are unwilling or not qualified to get a low-dose radiation CT scan,” Imidex CEO, Wes Bolsen said

Building Synergy

The Imidex Orbit Genomics partnership will allow the two tech companies to leverage the strength of their equipment to facilitate early cancer detection. The two companies plan to use Imidex’s VisiRad XR to identify lung nodules in patients. The results will be passed on to Orbit for testing of identified lung nodules with the help of OrbiSeq-L.

“Imidex’s technology is the top of the lung cancer identification funnel, utilizing chest X-rays rather than CT scans to detect potential cancer patients who might otherwise go undiagnosed. Orbit Genomics can then immediately test those identified lung nodule patients with OrbiSeq-L, providing highly specific insights from a simple blood sample into their condition and directing them to the most effective forms of care,” Orbit Genomics President, Dede Willis said in a statement.

Besides cancer detection, the OrbiSeq technology can be used to detect a wide range of diseases including neurological disorders and heart conditions.

Emerging Trend

The Imidex Orbit partnership to detect early lung cancer isn’t the first for the two companies. In July this year, Imidex collaborated with Spesana to monitor the impact of AI in boosting mass and lung nodule detection. The two companies are focused on quantifying downstream detection rates for lung cancer.

The companies are also working towards identifying high-risk patients for clinical trials. They do this through screening and evaluation of potential application of liquid biopsies that result from nodule detection.

Early this month, Orbit Genomics completed the CancerX Accelerator Program that’s focused on digital innovation and cancer intersection. Initiated by the US Department of Health and Human services, CancerX is focused on enhancing cancer innovation in the country.

The program involved hands-on learning and months of mentorship at the Moffitt Cancer Center.

Related Articles: How Revolutionary AI Model Detects Underlying Heart Attacks Risks

The post Orbit Genomics, Imidex Technologies Enable Early Lung Cancer Detection appeared first on Tech Research Online.

People who do not have these conditions can buy the monitors without a prescription. Continuous glucose monitors (CGMs) are tiny sensors that poke through the skin and measure glucose levels in real time.

Non-Prescription Product

Stelo comes with a wearable sensor that pairs with an app in the user’s smart device to continuously monitor glucose levels. For diabetes patients, the sensors help in alerting users, their doctors, and loved ones to emergencies.

“We’re excited to empower people to have access to their glucose readings. We know studies have been done time and time again- giving people continuous glucose monitors helps improve their time in range, their A1c, and their sense of well-being living with diabetes. We expect the same improvements with this product that we’ve had with the G series products,” Dexcom Head of Clinical Advocacy and Outcomes, Thomas Grace said.

According to a statement by Dexcom, 125 million people who have Type 2 diabetes or prediabetes don’t use insulin. Stelo glucose sensor is designed to educate this population how to maintain a healthy range of glucose.

“The idea is to help people, over time, learn about diet choices and habits, and how those are impacting glucose. It’s about uncovering things you haven’t seen before and then using that to create healthier habits,” Jake Leach, Dexcom’s Chief Operating Officer said.

Dexcom already offers glucose monitors for Type 1 and Type 2 diabetes patients on a prescription basis. However, Stelo is the first monitor that patients can access without a prescription.

FDA Approval

Stelo is the first over-the-counter continuous glucose monitor to receive the US Food and Drug Administration nod. The agency cleared it for use in March this year. In June, the FDA cleared two similar devices for Dexcom’s rival, Abbott Laboratories.

The continuous glucose monitors, Libre Rio and Lingo are designed for adults with and without diabetes respectively. Abbott’s FDA-approved Lingo CGMs were to be launched in the US this summer.

Stelo informs users of noteworthy glucose spikes. According to Dexcom, this intentional design is meant to raise alerts on larger swings that patients experience.

“Even for someone who has normal glucose and the occasional spike, it’ll look for the most impactful spikes and then try to engage the user around, ‘OK, what happened there?” Leach said.

Users who wish to understand the cause of glucose spikes can explore educational content available on the Stelo app’s ‘Learn’ sections.

Highly Accessible

Users have the option of buying monthly supplies of Dexcom over-the-counter continuous glucose sensors online at $99. Alternatively, they can sign up for monthly subscriptions at $89 per month. Patients have the option of using health savings accounts and spending accounts to pay for Stelo.

Most Type 1 patients can get insurance coverage for glucose monitors. However, millions of Type 2 patients who lack prescription or coverage now have access to Stelo. This allows Dexcom to expand its reach in the lucrative prediabetes market.

Dexcom has partnered with Amazon to fulfill Stelo orders. Monthly subscribers can opt to adjust or skip delivery dates. However, deliveries will be scheduled in 30-day intervals from the date of initial sign-up.

The post Dexcom Makes Glucose Monitors Available Over-the-Counter appeared first on Tech Research Online.

Unveiling of Two Products

The Sonova AI hearing aid is the first of its kind in the world. The launch of the new product, which is marketed as Sphere Infinio, increased Sonova’s share prices by 5%. Besides the hearing aid product, Sonova also launched a new Infinio platform.

“The launch of both the new platform and product should be a surprise to the market, because nobody knew this technology and this benefit (real-time AI), which is quite significant, will be available for anyone already this year,” CEO Arnd Kaldowski said.

Research Partners AG analyst, Urs Kunz said the launch was a big step for Sonova.

High Processing Power

Sonova’s real time AI hearing aid is powered by DEEPSONIC chip technology. This new technology’s processing power is 53 times more than what is used in the hearing aid industry currently.

The company sees its Sonova hearing aid and its Lumity platform as important growth drivers of its hearing products business. This business contributes about 50% of its total sales.

Annual Profit Targets

Sonova has managed to stick to its full year profit targets as rivals such as Amplifon of Italy, GN Store Nord, and Demant of Denmark released profit warnings this summer.

“Our first impression is that Sonova has launched an interesting product platform, which is likely to accelerate growth in H2 2024/25,” Niels Granholm-Leth, a Carnegie Analyst said.

European and American markets are showing signs of soft dynamics for the hearing aid industry. But market analysts have highlighted tough competition as the market evolves.

“We will need to see how the market evolves and the customer reaction to the products. But we are good with our full year guidance even with the currently somewhat slower market,” Kaldowski said.

Earlier this year, Sonova said that it expected the launch of its hearing aid with real time AI product to boost sales revenue and grow its profits in the second half of the year.

The post Sonova Unveils AI Hearing Aid with High Processing Power appeared first on Tech Research Online.

The UK’s NHS is backing a pilot project across five hospitals in Milton Keynes, Oxford, Liverpool, Leicester, and Wolverhampton. A decision on whether the technology will be adopted by the NHS is expected in the coming months.

Transformative Technology

The AI model was developed by Oxford University’s spin off company, Caristo Diagnostics. It’s capable of detecting heart inflammation that CT scans don’t detect. Caristo Diagnostics says its team is working to adapt the AI to diabetes and stroke prevention.

“This technology is transformative and game changing because, for the first time, we can detect the biological processes that are invisible to the human eye, which precedes the development of narrowings and blockages [within the heart],” Oxford University’s Prof. Keith Channon said.

During the pilot phase, Caristo Diagnostics analyzed CT scans from patients who experience chest pains and are referred for routine scans using its CaRi-Heart AI platform.

An algorithm that detects coronary plaque and inflammation is assessed by professional operations to ensure accuracy.

High Risk

Research shows that inflammation raises the risk of fatal heart attacks and cardiovascular disease. According to the British Heart Foundation (BHF), an estimated 7.6 million people in the U.K. suffer from heart disease. An estimated 350,000 patients are referred for cardiac CT scan annually. Government statistics show that the NHS spends about $9.5 billion (£7.4 billion) annually on heart disease patients.

An ORFAN study that focused on inflammatory risk factors involving 40,000 patients found that 80% of people were referred back to primary care without a clear treatment or prevention plan. Researchers in this study reported that patients who developed inflammation in coronary arteries had a high hidden heart attack risk and were 20 to 30 times more likely to die from cardiac disease in the next 10 years.

The study also found that AI technology helped 42% of these patients. The technology reduced AI heart attack risk by motivating patients to make lifestyle changes or prescribing meditation.

Reality Check

One patient, Ian Pickard, from Leicestershire experienced persistent chest pains. Pickard, 58, was sent for a CT scan in 2023 and participated in the ORFAN study. After undergoing AI analysis, results suggested that he was at a high risk of suffering a heart attack.

Pickard was asked to quit smoking and increase physical activity. He also got a prescription for statins.

“It’s a huge wake-up call. And when you see it on paper, you realize how serious it is. It’s something you can look at each day and think, ‘I’ve got to do something about this“, Pickard said.

Early Detection

According to the ORFAN study lead researcher, Prof. Charalambos Antoniades, the tools that have been available to date only assess general patient risks. The new AI heart attack tool changes this.

“With this kind of AI technology, we know exactly which patient had the disease activity in their arteries before the disease even developed. This means we can move early to end the disease process and treat this patient to prevent the disease from developing and then prevent heart attacks from happening.”

Currently, the National Institute for Health and Care Excellence is assessing the AI model to see whether it should be applied throughout NHS facilities. The technology has been approved in Australia and Europe. It is also being reviewed in the US.

The post How Revolutionary AI Model Detects Underlying Heart Attacks Risks appeared first on Tech Research Online.

Stop the Revenue Drain: Conquer Claim Denials & Accelerate Payments

Simplify patient payments. Watch revenue soar.

Are you a healthcare provider drowning in a sea of claim denials, payment delays, and endless paperwork? Are you tired of watching your hard-earned revenue slip through the cracks due to a complex and inefficient billing process? It’s time to reclaim control, optimize your revenue cycle, and get paid faster. 

In This Free Webinar, You’ll Discover:

• The Challenges: Why claim denials, delays, and audits are so common in today’s healthcare landscape.
• The Solution: How technology can streamline your claims process, reduce errors, and accelerate payments.
• The Inovolon Advantage: Why our all-in-one platform is the key to simplifying your billing workflow and improving your bottom line.

Join Webinar

Join Webinar

[contact-form-7]

The post Stop the Revenue Drain: Conquer Claim Denials & Accelerate Payments appeared first on Tech Research Online.

Skilled Nursing Group Gets Paid Faster, Sees Fewer Denials with Inovalon

See how HMG Healthcare Improved Cash Flow and Efficiency  

Is slow reimbursement and high denial rates impacting your skilled nursing facility’s bottom line? HMG Healthcare faced similar challenges until they implemented Inovalon’s innovative software solutions. Learn how they transformed their revenue cycle management, improved cash flow, and enhanced patient satisfaction. 

In this case study you will learn how about:

• HMG Healthcare overcame the challenges of slow reimbursements and high denial rates.
• Inovalon’s software helped streamline the claims management process.
• The impact of faster claim processing on cash flow.
• How HMG Healthcare increased their clean claim rate and reduced denials.
• The role of technology in improving patient experience.

Download the case study

Download the case study

[contact-form-7]

The post Skilled Nursing Group Gets Paid Faster, Sees Fewer Denials with Inovalon appeared first on Tech Research Online.